Hospital & Healthcare Services · Founded 1994 · www.scandent.in · BSE 516110 · · ISIN INE146N01016
No Notes Added Yet
Business
Family Care Hospitals Ltd. operates within the Hospital & Healthcare Services sector in India. Its core business involves establishing and managing hospitals, providing a range of medical services to patients. This typically includes inpatient and outpatient care, emergency services, surgical procedures, diagnostic services, and pharmacy operations. The company's business model revolves around generating revenue from patient services, which can include consultations, room charges, surgical fees, diagnostic tests, and sales of medicines. They likely cater to a mix of insured, self-paying, and potentially government-scheme-covered patients, aiming to provide accessible healthcare services.
Revenue Mix
Without specific financial data for Family Care Hospitals Ltd., typical revenue streams for a multi-specialty hospital chain in India include:
Inpatient Services: Revenue from patient admissions, bed charges, intensive care, and major surgeries (often the largest contributor).
Outpatient Services: Consultations, minor procedures, day care surgeries, and emergency room visits.
Diagnostics & Pharmacy: Income generated from laboratory tests, imaging services (MRI, CT scans), and sales of pharmaceuticals within the hospital premises.
Specialty Departments: Revenue can also be segmented by medical specialties like Cardiology, Orthopedics, Oncology, Neurology, etc., which often command different pricing and volumes.
A precise percentage breakdown is not publicly available without further specific company disclosures.
Industry
The Hospital & Healthcare Services industry in India is highly dynamic, characterized by a mix of large corporate hospital chains, regional players, single-specialty hospitals, and numerous standalone clinics. While fragmented, the industry is witnessing increasing consolidation, with corporate players expanding their footprint. Given the company's name and general market context, Family Care Hospitals Ltd. is likely positioned as a regional or mid-sized healthcare provider, potentially focusing on specific geographic areas or offering a mix of affordability and quality to a broad patient base. Its positioning relative to larger, well-established national chains would be as a challenger or niche player, possibly emphasizing community healthcare or specific specialty services.
MOAT
For a hospital chain, potential competitive advantages (moats) could include:
Brand & Reputation: Trust built over time through consistent quality of care, positive patient outcomes, and ethical practices.
Doctor Talent & Expertise: Ability to attract and retain highly skilled medical professionals and specialists.
Strategic Location: Hospitals situated in high-density population areas with easy accessibility.
Operational Scale (for larger players): Cost efficiencies in procurement, better bargaining power with suppliers, and standardized processes.
Referral Network: Strong relationships with referring physicians and clinics.
It is challenging to ascertain the specific strength of Family Care Hospitals Ltd.'s moat without detailed operational and market data. While all hospitals strive for good reputation and talent, building a durable competitive advantage that significantly differentiates them from peers often requires substantial scale, niche expertise, or a deeply entrenched brand in specific geographies.
Growth Drivers
Key factors that can drive growth for Family Care Hospitals Ltd. over the next 3-5 years include:
Rising Healthcare Expenditure: Increasing disposable incomes and greater health awareness among the Indian population.
Expanding Health Insurance Penetration: Growth in both government-backed schemes (e.g., Ayushman Bharat) and private health insurance.
Demographic Shifts: An aging population and an increasing burden of lifestyle diseases requiring specialized medical care.
Infrastructure Deficit: Continued demand for quality healthcare infrastructure, especially in Tier 2/3 cities and underserved areas.
Medical Tourism: Potential to attract international patients, depending on quality, cost-effectiveness, and specialty offerings.
Technological Advancement: Adoption of new medical technologies and digital health solutions to improve efficiency and patient care.
Risks
Key business risks include:
Intense Competition: High competition from existing players, new entrants, and standalone specialty clinics, leading to pricing pressures.
Regulatory & Policy Changes: Government interventions regarding pricing caps on medical procedures, drugs, and implants, as well as changes in land allocation or operational licenses.
Talent Acquisition & Retention: Shortage of skilled doctors, nurses, and paramedical staff, leading to higher wage costs or operational challenges.
High Capital Expenditure: Significant ongoing investment required for facility expansion, technology upgrades, and equipment maintenance.
Reputational Risks: Adverse events, medical malpractice claims, or negative publicity can severely impact patient trust and revenue.
Reimbursement Pressures: Delays or reductions in payments from insurance providers or government schemes.
Economic Downturns: Reduced discretionary spending on healthcare for elective procedures or a shift towards more affordable alternatives.
Management & Ownership
As is common with many Indian companies, Family Care Hospitals Ltd. is likely to be promoter-led, with the founding family or individuals holding a significant stake and playing a crucial role in strategic decision-making. Information regarding the specific quality of management (e.g., track record, governance practices, succession planning) or the detailed ownership structure (promoter vs. institutional vs. public holdings) is not available without access to specific company filings or investor presentations.
Outlook
Family Care Hospitals Ltd. operates in an industry with significant long-term tailwinds driven by demographic shifts, increasing health awareness, and rising incomes in India. The sustained demand for quality healthcare services presents a strong growth opportunity. However, the company faces substantial challenges including intense competition, the need for continuous capital investment, and the potential for regulatory interventions that could impact profitability. Its success will depend on its ability to effectively scale operations, attract and retain medical talent, maintain a strong brand reputation for quality care, and navigate the evolving regulatory landscape while managing operational efficiencies. Future performance will hinge on its execution strategy in expanding its footprint, enhancing its service offerings, and building a durable competitive advantage in its chosen markets.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 6 | 4 | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Total Expenditure | 3 | 4 | -27 | 2 | 1 | 0 | 4 | 1 | -2 | 0 |
| Operating Profit | 3 | 1 | 32 | -2 | 1 | -0 | -4 | -1 | 2 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | -75 | 0 | 0 | 0 | 0 | 0 | -4 | 0 |
| Profit Before Tax | 3 | 0 | -43 | -2 | 1 | -1 | -5 | -1 | -2 | -0 |
| Provision for Tax | -6 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 9 | 0 | -43 | -2 | 1 | -1 | -5 | -1 | -2 | -0 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Adjustments | 9 | 0 | -43 | -2 | 1 | -1 | -5 | -1 | -2 | -0 |
| Adjusted Earnings Per Share | 1.6 | 0 | -8 | -0.4 | 0.2 | -0.1 | -0.9 | -0.2 | -0.4 | -0.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 1 | 2 | 5 | 14 | 13 | 35 | 42 | 42 | 40 | 8 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 0 |
| Total Income | 0 | 1 | 2 | 5 | 14 | 13 | 35 | 42 | 43 | 43 | 11 | 0 |
| Total Expenditure | 0 | 1 | 2 | 4 | 13 | 11 | 27 | 33 | 34 | 33 | -21 | 3 |
| Operating Profit | -0 | 0 | 0 | 2 | 2 | 2 | 8 | 9 | 9 | 10 | 32 | -3 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | -25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -75 | -4 |
| Profit Before Tax | -25 | 0 | 0 | 1 | 0 | 0 | 6 | 7 | 7 | 8 | -44 | -8 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | -4 | -0 | 0 |
| Profit After Tax | -25 | 0 | 0 | 1 | 0 | 0 | 4 | 5 | 5 | 13 | -44 | -8 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -25 | 0 | 0 | 1 | 0 | 0 | 4 | 5 | 5 | 13 | -44 | -8 |
| Adjusted Earnings Per Share | -7.1 | 0 | 0 | 0.2 | 0 | 0 | 1.2 | 1.5 | 1 | 2.3 | -8.2 | -1.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -80% | -42% | -9% | 0% |
| Operating Profit CAGR | 220% | 53% | 74% | 0% |
| PAT CAGR | -438% | NAN% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -59% | -37% | -38% | -16% |
| ROE Average | -123% | -27% | 4% | -123% |
| ROCE Average | -112% | -24% | 3% | -94% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 4 | 4 | 5 | 5 | 5 | 9 | 14 | 46 | 58 | 13 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 6 | 7 | 4 | 2 | 1 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 1 | 0 |
| Total Current Liabilities | 1 | 1 | 1 | 5 | 3 | 5 | 5 | 20 | 22 | 10 | 32 |
| Total Liabilities | 5 | 5 | 5 | 10 | 14 | 17 | 20 | 40 | 75 | 70 | 46 |
| Fixed Assets | 2 | 2 | 2 | 7 | 9 | 10 | 8 | 7 | 7 | 6 | 4 |
| Other Non-Current Assets | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 1 | 9 | 9 | 1 |
| Total Current Assets | 3 | 3 | 2 | 0 | 3 | 6 | 11 | 32 | 59 | 55 | 41 |
| Total Assets | 5 | 5 | 5 | 10 | 14 | 17 | 20 | 40 | 75 | 70 | 46 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 3 | 3 | 2 | 0 | 0 | 2 | 0 | 0 | 19 | 17 |
| Cash Flow from Operating Activities | -0 | 0 | 0 | 3 | -3 | 0 | 4 | 2 | -5 | -0 | -17 |
| Cash Flow from Investing Activities | -2 | -0 | -1 | -5 | -2 | -2 | -0 | -0 | -2 | -0 | 1 |
| Cash Flow from Financing Activities | 5 | -0 | 1 | 0 | 5 | 3 | -5 | -2 | 26 | -1 | -1 |
| Net Cash Inflow / Outflow | 3 | -0 | -0 | -2 | 0 | 1 | -1 | -0 | 19 | -2 | -17 |
| Closing Cash & Cash Equivalent | 3 | 3 | 2 | 0 | 0 | 2 | 0 | 0 | 19 | 17 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -7.1 | 0.01 | 0.05 | 0.25 | 0.01 | 0.01 | 1.16 | 1.49 | 0.97 | 2.32 | -8.17 |
| CEPS(Rs) | -7.09 | 0.12 | 0.12 | 0.36 | 0.27 | 0.37 | 1.57 | 1.9 | 1.23 | 2.59 | -7.96 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.05 | 0 | 0 |
| Book NAV/Share(Rs) | 1.12 | 1.12 | 1.17 | 1.41 | 1.42 | 1.43 | 2.59 | 4.07 | 8.48 | 10.81 | 2.49 |
| Core EBITDA Margin(%) | -255.81 | 19.61 | 15 | 25.95 | 10.3 | 16.18 | 22.29 | 20.65 | 19.95 | 16.96 | 359.96 |
| EBIT Margin(%) | 0 | 2.43 | 11.72 | 23.08 | 3.98 | 6.67 | 18.34 | 17.98 | 18.94 | 21.38 | -558.42 |
| Pre Tax Margin(%) | 0 | 1.89 | 10.9 | 20.83 | 0.38 | 0.29 | 15.99 | 16.79 | 17.65 | 20.33 | -562.54 |
| PAT Margin (%) | 0 | 1.89 | 8.76 | 16.52 | 0.13 | 0.21 | 11.52 | 12.36 | 12.5 | 31.36 | -558.48 |
| Cash Profit Margin (%) | 0 | 37.8 | 22.47 | 24.08 | 6.75 | 9.85 | 15.53 | 15.78 | 15.86 | 34.91 | -544.23 |
| ROA(%) | -1085.04 | 0.44 | 3.13 | 11.15 | 0.16 | 0.18 | 21.72 | 17.27 | 9.19 | 17.36 | -76.08 |
| ROE(%) | -1394.79 | 0.51 | 3.92 | 18.96 | 0.38 | 0.57 | 57.85 | 44.6 | 17.51 | 24.09 | -122.91 |
| ROCE(%) | -1096.64 | 0.58 | 4.85 | 25.41 | 7.15 | 7.03 | 44.54 | 45.74 | 23.2 | 15.25 | -111.92 |
| Receivable days | 0 | 0 | 0 | 0 | 64.51 | 90.92 | 67.74 | 132.27 | 219.11 | 287.56 | 832.09 |
| Inventory Days | 0 | 0 | 0 | 4.78 | 3.27 | 6.59 | 3.07 | 1.97 | 1.76 | 4.09 | 892.88 |
| Payable days | 0 | 0 | 0 | 365 | 682.71 | 1079.33 | 199.67 | 218.23 | 383.2 | 264.32 | -165.61 |
| PER(x) | 0 | 1306.35 | 336.05 | 69.26 | 0 | 1240.66 | 12.21 | 12.13 | 11.55 | 3.01 | 0 |
| Price/Book(x) | 0 | 6.71 | 12.94 | 12 | 0 | 7.04 | 5.48 | 4.43 | 1.33 | 0.65 | 1.44 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.51 | 0.44 | 0 | 0 |
| EV/Net Sales(x) | 439.21 | 22.78 | 28.19 | 11.45 | 2.62 | 3.26 | 1.55 | 1.6 | 1.09 | 0.6 | 2.85 |
| EV/Core EBITDA(x) | -477.31 | 59.41 | 110.85 | 37.38 | 24.76 | 20.02 | 6.94 | 7.46 | 4.88 | 2.4 | 0.71 |
| Net Sales Growth(%) | 408.47 | 1470.67 | 68.01 | 188.56 | 173.48 | -6.65 | 166.91 | 18.98 | -0.05 | -4.84 | -80.24 |
| EBIT Growth(%) | -7300.74 | 100.1 | 711.32 | 468.23 | -52.79 | 56.2 | 634.24 | 16.63 | 5.29 | 7.42 | -616.1 |
| PAT Growth(%) | -7297.91 | 100.08 | 680.99 | 444.18 | -97.77 | 49.12 | 0 | 27.61 | 1.12 | 138.67 | -451.82 |
| EPS Growth(%) | -591.41 | 100.08 | 679.37 | 443.99 | -97.77 | 49.12 | 0 | 27.61 | -34.49 | 138.67 | -451.82 |
| Debt/Equity(x) | 0.14 | 0.14 | 0.02 | 0.06 | 1.13 | 1.9 | 0.61 | 0.3 | 0.09 | 0.06 | 0.25 |
| Current Ratio(x) | 4.61 | 4.38 | 1.75 | 0.1 | 1.03 | 1.19 | 2.08 | 1.59 | 2.65 | 5.51 | 1.28 |
| Quick Ratio(x) | 4.61 | 4.38 | 1.75 | 0.08 | 0.97 | 1.14 | 2.02 | 1.58 | 2.64 | 5.45 | 0.1 |
| Interest Cover(x) | 0 | 4.48 | 14.33 | 10.26 | 1.1 | 1.05 | 7.8 | 15.18 | 14.66 | 20.31 | -135.48 |
| Total Debt/Mcap(x) | 0 | 0.02 | 0 | 0 | 0 | 0.27 | 0.11 | 0.07 | 0.07 | 0.1 | 0.17 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 17.47 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Public | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 82.44 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.94 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.45 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -80% | -42% | -9% | — |
| Operating Profit CAGR | +220% | +53% | +74% | — |
| PAT CAGR | -438% | 0% | — | — |
| Share Price CAGR | -59% | -37% | -38% | -16% |
| ROE Average | -123% | -27% | +4% | -123% |
| ROCE Average | -112% | -24% | +3% | -94% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 | 17.47 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Public | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 81.37 | 82.44 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.94 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 | 4.45 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.